Viewing Study NCT00257829



Ignite Creation Date: 2024-05-05 @ 12:08 PM
Last Modification Date: 2024-10-26 @ 9:21 AM
Study NCT ID: NCT00257829
Status: WITHDRAWN
Last Update Posted: 2018-12-03
First Post: 2005-11-21

Brief Title: Improving Tumor Oxygenation in Cervical Cancer
Sponsor: University of California Irvine
Organization: University of California Irvine

Study Overview

Official Title: Improving Tumor Oxygenation in Cervical Cancer With Methazolamide
Status: WITHDRAWN
Status Verified Date: 2018-11
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: This study was closed due to lack of funding
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The Phenomenon of Tumor Hypoxia Many solid tumors are relatively resistant to treatment with ionizing radiation and certain chemotherapeutic agents such as anthracyclines that are affected adversely by acidic pH These effects have primarily been attributed to the presence of hypoxic cells within the tumor The relevance of hypoxia with respect to failure of radiotherapy to cure certain malignancies has had a chequered history However in recent years the evidence that hypoxia plays a central role in relative radioresistance has become more compelling

Since approximately two-thirds of all women suffering from cervical carcinoma receive radiation as a component of their therapy an enhanced understanding of the interactions between hypoxia and radiation as a component of their therapy an enhanced understanding of the interactions between hypoxia and radiation resistance is critical to improving outcome among those with cervical cancer
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None